Patents by Inventor Sauro BONELLI

Sauro BONELLI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stainless steel can for pressurised metered dose inhalers
    Patent number: 12616654
    Abstract: The invention generally refers to a stainless steel can for use in a metered dose inhaler device, containing an aerosol formulation, comprising glycopyrronium bromide and formoterol, or a salt or a solvate thereof, optionally in combination with one or more additional active ingredient, endowed with a high stability.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: May 5, 2026
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Enrico Zambelli, Sauro Bonelli, Diego Copelli, Massimiliano Dagli Alberi, Francesca Usberti
  • A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER
    Publication number: 20250312274
    Abstract: The present invention generally relates to pharmaceutical composition comprising a LABA agent, optionally in combination with other active ingredients, a mixture of an acid and a chelating agent, a propellant and a co-solvent. The invention also provides a pharmaceutical composition for the treatment of respiratory diseases, such as asthma and COPD.
    Type: Application
    Filed: May 26, 2023
    Publication date: October 9, 2025
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Enrico ZAMBELLI, Sauro BONELLI, Angelo Benedetto MATTURRO, Francesca USBERTI, Alessandro CAVECCHI
  • A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER
    Publication number: 20250302742
    Abstract: The present invention generally relates to pharmaceutical composition comprising a LABA agent, optionally in combination with other active ingredients, a chelating agent, a propellant and a co-solvent. The invention also provides a pharmaceutical composition for the treatment of respiratory diseases, such as asthma and COPD.
    Type: Application
    Filed: May 26, 2023
    Publication date: October 2, 2025
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Enrico ZAMBELLI, Sauro BONELLI, Angelo Benedetto MATTURRO, Francesca USBERTI, Alessandro CAVECCHI
  • AEROSOL FORMULATION FOR COPD
    Publication number: 20250262151
    Abstract: Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions.
    Type: Application
    Filed: May 9, 2025
    Publication date: August 21, 2025
    Inventors: Sauro Bonelli, Francesca Usberti, Enrico Zambelli
  • Aerosol formulation for COPD
    Patent number: 12357568
    Abstract: Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions.
    Type: Grant
    Filed: January 11, 2023
    Date of Patent: July 15, 2025
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Sauro Bonelli, Francesca Usberti, Enrico Zambelli
  • PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER
    Publication number: 20250082588
    Abstract: The present invention generally relates to pharmaceutcial composition comprising a LABA agent, a LAMA agent, optionally in combination with other active ingredients, a mixture of an acid and a chelating agent, a propellant and a co-solvent. The invention also provides a pharmaceutical composition for the treatment of respiratory diseases, such as asthma and COPD.
    Type: Application
    Filed: November 26, 2024
    Publication date: March 13, 2025
    Inventors: Enrico Zambelli, Sauro Bonelli, Angelo Benedetto Matturro, Francesca Usberti, Alessandro Cavecchi
  • A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER
    Publication number: 20230277451
    Abstract: The present invention generally relates to pharmaceutical composition comprising a LABA agent, optionally in combination with other active ingredients, a mixture of at least two inorganic acids, a propellant and a co-solvent. The invention also provides a pharmaceutical composition for the treatment of respiratory diseases, such as asthma and COPD.
    Type: Application
    Filed: October 8, 2021
    Publication date: September 7, 2023
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Enrico ZAMBELLI, Sauro BONELLI, Diego COPELLI, Massimiliano DAGLI ALBERI, Francesca USBERTI
  • AEROSOL FORMULATION FOR COPD
    Publication number: 20230157951
    Abstract: Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions.
    Type: Application
    Filed: January 11, 2023
    Publication date: May 25, 2023
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Sauro BONELLI, Francesca USBERTI, Enrico ZAMBELLI
  • Aerosol formulation for COPD
    Patent number: 11590074
    Abstract: Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: February 28, 2023
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Sauro Bonelli, Francesca Usberti, Enrico Zambelli
  • STAINLESS STEEL CAN FOR PRESSURISED METERED DOSE INHALERS
    Publication number: 20220395454
    Abstract: The invention generally refers to a stainless steel can for use in a metered dose inhaler device, containing an aerosol formulation, comprising glycopyrronium bromide and formoterol, or a salt or a solvate thereof, optionally in combination with one or more additional active ingredient, endowed with a high stability.
    Type: Application
    Filed: December 2, 2019
    Publication date: December 15, 2022
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Enrico ZAMBELLI, Sauro BONELLI, Diego COPELLI, Massimiliano DAGLI ALBERI, Francesca USBERTI
  • Combination therapy for COPD
    Patent number: 11389401
    Abstract: Aerosol formulations comprising glycopyrronium bromide in combination with formoterol are useful for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium bromide and the formoterol components. Optionally the formulation may further comprise beclometasone dipropionate.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: July 19, 2022
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Sauro Bonelli, Francesca Usberti, Enrico Zambelli
  • AEROSOL FORMULATION FOR COPD
    Publication number: 20210000738
    Abstract: Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions.
    Type: Application
    Filed: September 14, 2020
    Publication date: January 7, 2021
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Sauro Bonelli, Francesca Usberti, Enrico Zambelli
  • Aerosol formulation for COPD
    Patent number: 10806701
    Abstract: Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: October 20, 2020
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Sauro Bonelli, Francesca Usberti, Enrico Zambelli
  • Stable pressurized aerosol solution composition of glycopyrronium bromide and formoterol combination
    Patent number: 10617669
    Abstract: Aerosol solution compositions intended for use with a pressurized metered dose inhaler, comprising glycopyrronium bromide and formoterol, or a salt thereof, optionally in combination with one or more additional active ingredients, and stabilized by a selected amount of a mineral acid, exhibit improved stability when contained in an aerosol can provided with a metering valve having at least a butyl rubber gasket.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: April 14, 2020
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Sauro Bonelli, Diego Copelli, Massimiliano Dagli Alberi, Francesca Usberti, Enrico Zambelli
  • Stable pressurized aerosol solution composition of glycopyrronium bromide and formoterol combination
    Patent number: 10617638
    Abstract: Aerosol solution compositions intended for use with a pressurized metered dose inhaler, comprising glycopyrronium bromide and formoterol, or a salt thereof or a solvate of said salt, optionally in combination with one or more additional active ingredients, and stabilized by a selected amount of a mineral acid, exhibit improved stability when contained in a can internally coated by a resin comprising a fluorinated ethylene propylene (FEP) polymer.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: April 14, 2020
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Sauro Bonelli, Diego Copelli, Massimiliano Dagli Alberi, Francesca Usberti, Enrico Zambelli
  • Stable pressurized aerosol solution composition of glycopyrronium bromide and formoterol combination
    Patent number: 10596113
    Abstract: Aerosol solution compositions intended for use with a pressurized metered dose inhaler, comprising glycopyrronium bromide and formoterol, or a salt thereof or a solvate of said salt, optionally in combination with one or more additional active ingredients, and stabilized by a selected amount of a mineral acid, exhibit improved stability when contained in a can internally coated by a resin comprising a fluorinated ethylene propylene (FEP) polymer.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: March 24, 2020
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Sauro Bonelli, Diego Copelli, Massimiliano Dagli Alberi, Francesca Usberti, Enrico Zambelli
  • Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
    Patent number: 10596149
    Abstract: Aerosol solution compositions intended for use with a pressurized metered dose inhaler, comprising glycopyrronium bromide and formoterol, or a salt thereof, optionally in combination with one or more additional active ingredients, and stabilized by a selected amount of a mineral acid, exhibit improved stability when contained in an aerosol can provided with a metering valve having at least a butyl rubber gasket.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: March 24, 2020
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Sauro Bonelli, Diego Copelli, Massimiliano Dagli Alberi, Francesca Usberti, Enrico Zambelli
  • COMBINATION THERAPY FOR COPD
    Publication number: 20190046433
    Abstract: Aerosol formulations comprising glycopyrronium bromide in combination with formoterol are useful for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium bromide and the formoterol components. Optionally the formulation may further comprise beclometasone dipropionate.
    Type: Application
    Filed: October 16, 2018
    Publication date: February 14, 2019
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Sauro BONELLI, Francesca USBERTI, Enrico ZAMBELLI
  • Combination therapy for COPD
    Patent number: 10159645
    Abstract: Aerosol formulations comprising glycopyrronium bromide in combination with formoterol are useful for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium bromide and the formoterol components. Optionally the formulation may further comprise beclometasone dipropionate.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: December 25, 2018
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Sauro Bonelli, Francesca Usberti, Enrico Zambelli
  • AEROSOL FORMULATION FOR COPD
    Publication number: 20180021301
    Abstract: The stable aerosol solution formulations comprising glycopyrronium chloride are useful for administration to patients with COPD and other respiratory conditions.
    Type: Application
    Filed: September 7, 2017
    Publication date: January 25, 2018
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Sauro Bonelli, Francesca Usberti, Enrico Zambelli